MicrobiotiX strives to develop treatments
 for global intractable diseases
such as multidrug-resistant
bacterial infections, autoimmune diseases and cancer


Phage, Microbiome
& Beyond


A bactericidal virus that uses bacteria as a host is called as "bacteriophage". The average size of bacteriophages is about 200 nanometers, about 1/8 of bacteria, and selectively sterilizes bacteria. This is because infection is possible only when the tail fiber of the bacteriophage is selectively adsorbed to a specific membrane protein also known as receptor protein of a bacteria. Bacteriophages can be found anywhere in the natural environment, such as soil, water, and seawater, and account for more than 90% of viruses in the human body and are harmless to the human body. In addition, it has a function of minimizing the occurrence of resistance by dramatically reducing the patient's antibiotic dose by removing the antibiotic-resistant strain and co-administration.

The Sea of Phages

Healthy people maintain a stable and balanced intestinal microbial ecosystem (microbiome). In other words, changes in the intestinal core bacteriophage and microbiome are delicately intertwined with human health (metabolites and immune system) Bacteriophages are used to balance and change intestinal microbiome through targeted bacterial removal, symbiosis with bacteria, and modulation.


Healthy Gut Phageome

Citation : Healthy human gut phageome Pilar Manrique, Benjamin Bolduc, Seth T. Walk, John van der Oost, Willem M. de Vos, Mark J. Young Proceedings of the National Academy of Sciences Sep 2016, 113 (37) 10400-10405; DOI: 10.1073/pnas.1601060113span>


Healthy people share
of key phages


Patients with Ulcerative colitis share 
of key phages


Patients with Crohn’s disease share
of key phages


Our pipeline will be expanded rapidly through the analysis of 1,000 new pathogens per month and discovering effective phages to fight against them. (NGS/PCS analysis to phage vs. microbiome, taxonomy, healthy patient phage comparison) to discover candidate drug substances and build optimized CMC to produce through our GMP.

Development of a Cure for Untreatable Diseases

MicrobiotiX aims to develop various treatments for untreatable diseases through bacteriophages that can target gram-negative, multidrug-resistant bacteria and through microbiome modulation to treat: pneumonia, sepsis, IBD, autism, obesity, diabetes, colon cancer, etc.


Pseudomonas aeruginosa

MP001 - Pneumonia
Including cystic fibrosis

Composition Fixed rate cocktail of 3 types of phages
Clinical use indications acute pneumonia infected with multidrug-resistant P. aeruginosa
Genetic modification natural, unmodified lytic bacteriophages
Target patient (Sputum bacterium culture) All age groups shedding P. aeruginosa in sputum

Dosage form liquid, 10 mL vial Combined administration Meropenem and others Storage duration and method After 2 years, a 1/10 tier reduction, 5 Celsius

PK/PD (half-life) 2~12 hours in a healthy person Usage and dosage amount 1x10^ ~ 5x10^9 CFU/ml bid (1Day 2times) / tid (1Day 3times) (for 2weeks) Route of administration intravenous shot

Safety Total AE occurrence, minimal to minor adverse events <10% (from treated patients)
In-vitro phage efficacy evaluation factors burst size (greater than 10 for each infected bacteria), latent period (less than 2 hours), and adsorption rate (less than 1x10^8 ml/hr)

Pseudomonas aeruginosa

Product MP001


Product MP002


Product MP003 - MP009 

Urinary Tract Infection
Inflammatory Bowel Disease
Sexually Transmitted Disease
Rheumatoid Arthritis

API Progress

390+ Phages

K. pneumoniae
P. aeruginosa
A. baumannii
E. coli

CMC(Chemical Manufacturing and Controls)






Severance Hospital Clinical Research Center #221   l   TEL : 02. 6379. 2649   l   E-mail : mx@microbiotix.net

Copyright © MICROBIOTIX. All rights reserved.

Privacy Policy     Prohibition of Unauthorized Email Collection